Table 3.
RNActive vaccines for infectious and cancerous diseases.
| Vaccine Platform | Disease Target | Antigen | Preclinical/ Clinical Setting | Immune Response | Ref. |
|---|---|---|---|---|---|
| RNActive | Cancer | Ovalbumin | Mice | - Induction of balanced adaptive immune responses - Induction of antigen-specific memory T cells |
[23] |
| RNActive | Cancer | Ovalbumin | Mice | - Promotion of immunostimulation at injection site and lymphoid organs - Induction of adaptive immunity |
[24] |
| RNActive CV7201 | Rabies | RABV-G | Mice Pigs | - Induction of high and stable antibody titers lasting for 1 year - Activation of CD4+/CD8+ T cells - Protection against lethal viral challenge |
[25] |
| RNActive CV9103, CV9104 | Advanced prostate cancer | PSA, PSCA, PSMA, STEAP1 ± PAP, MUC1 | Phase I/II clinical trials (NCT00831467/ NCT01817738) | - Development of antigen-specific T cell immunity directed against multiple antigens | [27], [28], [29] |
| RNActive CV9201, CV9202 | Non-small cell lung cancer | MAGE-C1, MAGE-C2, NY-ESO-1, BIRC5, 5T4 ± MUC1 | Phase I/II clinical trials (NCT01915524) | - Induction of T and B cell responses against all included antigens - Increase of pre-germinal center B cells |
[30,31] |
| RNActive CV7201 | Rabies | RABV-G | Phase I clinical trial (NCT02241135) | - Induction of virus-neutralizing antibody titers ≥ 0.5 IU/ml | [32] |